Mara Franscaroli

Dirigente medico

Quaquarini E, Lasagna A, Schmid M, Sottotetti F, Nieswandt V, Pavesi L, Frascaroli M. Uveitis masquerade syndrome in a patient with metastatic lung adenocarcinoma. Italian Journal of Medicine. Volume 10 (s2) 98 (2016);

Sottotetti F, Nieswandt V, Lasagna A, Quaquarini E, Frascaroli M, Cavallo P, Magnani L, Pavesi L. Immune-related adverse events in a patient receiving anti PD1 antibody for lung cancer. Volume 10 (s2) 108 (2016);

num. A70 : “Factors affecting recurrence risk in HER2 positive DCIS”;

Authors: P. Di Cesare, L. Pavesi, L. Villani, M. Frascaroli IRCCS Fondazione Salvatore Maugeri, Pavia pubblicato su Annals of Oncology, Volume 26 supplement 6, 2015 (17h National Congress of Medical Oncology, 23-25 October 2015 Rome, Italy).

Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib. Frascaroli M, Di Cesare P.Tumori. 2014 Nov-Dec;100(6):e301-4. doi: 10.1700/1778.19306;

Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey. Cortinovis D, Beretta G, Piazza E, Luchena G, Aglione S, Bertolini A, Buzzoni R, Cabiddu M, Carnaghi C, Danova M, Farina G, Ferrari V, Frascaroli M, Reni M, Tansini G; AIOM Lombardia.Tumori. 2013 Jan-Feb;99(1):45-50. doi: 10.1700/1248.13787;

Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials. Strada MR, Palumbo R, Bernardo A, Riccardi A, Teragni C, Poggi G, Frascaroli M, Amatu A, Montagna B, Sottotetti F, Tagliaferri B, Bernardo G.Clin Breast Cancer. 2012 Feb;12(1):30-9. doi: 10.1016/j.clbc.2011.11.001. Epub 2011 Dec 6.